Neurogene Inc.
NGNE
Rank in Stocks
#13162
Neurogene Inc. is dedicated to engineering transformative genetic treatments... Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Share Price
$26.00
Last synced: 2026-11-09
Market Cap
$410.86M
Change (1 day)
2.73%
Change (1 year)
-16.34%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Neurogene Inc. (NGNE)
Category
Healthcare
Operating Margin for Neurogene Inc. (NGNE)
Operating Margin as of November 2026 TTM: 0.00%
According to Neurogene Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Neurogene Inc. from 2011 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | -100.00% |
| 2024 | -8,930.27% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | -100.00% |
| 2018 | -94.10% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
| 2011 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Neurogene Inc.'s operating margin
What was Neurogene Inc.'s operating margin in 2025?
In 2025, Neurogene Inc.'s operating margin was 0.00%, compared with -8,930.27% in 2024.
How has Neurogene Inc.'s operating margin changed since 2020?
From 2020 to 2025, Neurogene Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2024 (-8,930.27%).
How does Neurogene Inc.'s operating margin compare with similar companies?
Neurogene Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.